Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan

  • Clinical and Epidemiological Study
  • Published:
Infection Aims and scope Submit manuscript

Abstract

Background

Though various clinical conditions of aspergillosis can occur, depending essentially on the host’s immunological status, the focus of research in North American and European countries has mainly been on invasive pulmonary aspergillosis in immunocompromised patients. There are, however, also many problems to overcome in chronic forms of aspergillosis. One of those problems is that there are no codified treatment guidelines for chronic pulmonary aspergillosis (CPA). Especially in Japan, this issue is more serious, because there are more cases with CPA due to the many aged people with past history of tuberculosis. Several clinical cases and case series have reported the usefulness of the various antifungal agents that are available. The new triazole, voriconazole, in particular, seems to be effective in the treatment of CPA. The aim of the present study is to evaluate the efficacy and safety of voriconazole in the treatment of CPA in non-immunocompromised patients.

Patients and methods

We conducted a prospective, open-label, non-comparative, multicenter study over a 2-year period. For inclusion in the study, patients with confirmed or probable CPA were recruited in 11 hospitals of the National Hospital Organization in Japan. Clinical, radiological, serological, and mycological data were collected at baseline and 12 weeks after treatment or at the end of treatment.

Results

Among 77 patients enrolled in the study, 71 patients (mean age 65.9 years, 56 males and 15 females) were eligible for the study. All of the eligible patients presented with underlying lung diseases, including sequelae of tuberculosis (n = 35), non-tuberculous mycobacterial lung disease (n = 8), chronic obstructive pulmonary disease (COPD) (n = 8), interstitial pneumonia (n = 7), cystic lung disease (n = 4), pneumothorax (n = 3), bronchial cancer (n = 1), and others (n = 5). Voriconazole was indicated in 48 cases (68 %) as the first-line treatment for CPA and 23 patients previously received other antifungal therapies. Based on a composite of clinical, radiologic, serological, and mycologic criteria, good response was seen in 43 patients (60.6 %), no response was observed in 19 patients (26.8 %), and 4 cases (5.6 %) got worse. Five patients (7.0 %) were unassessable for efficacy. The common adverse events were visual disturbances (17 patients, 23.9 %), abnormal liver function test results (12 patients, 16.9 %), adverse psychological effects (3 patients, 4.2 %), and others (10 patients, 14.0 %). Treatment with voriconazole had to be stopped in 2 cases (2.8 %) because of serious adverse events (abnormal liver function test results). There was no association between adverse effects and trough voriconazole levels in serum.

Conclusions

In Japan, voriconazole provides effective therapy of CPA in non-immunocompromised patients with an acceptable level of toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408–15.

    Article  PubMed  CAS  Google Scholar 

  2. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, Heussel CP, Lortholary O, Rieger C, Boehme A, Aoun M, Horst HA, Thiebaut A, Ruhnke M, Reichert D, Vianelli N, Krause SW, Olavarria E, Herbrecht R; AmBiLoad Trial Study Group. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44:1289–97.

    Article  PubMed  CAS  Google Scholar 

  3. Gefter WB, Weingrad TR, Epstein DM, Ochs RH, Miller WT. “Semi-invasive” pulmonary aspergillosis: a new look at the spectrum of Aspergillus infections of the lung. Radiology. 1981;140:313–21.

    PubMed  CAS  Google Scholar 

  4. Binder RE, Faling LJ, Pugatch RD, Mahasaen C, Snider GL. Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity. Medicine (Baltimore). 1982;61:109–24.

    Article  CAS  Google Scholar 

  5. Denning DW, Riniotis K, Dobrashian R, Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis. 2003;37:S265–80.

    Article  PubMed  Google Scholar 

  6. Smith NL, Denning DW. Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J. 2011;37:865–72.

    Article  PubMed  CAS  Google Scholar 

  7. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF; Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327–60.

    Article  PubMed  CAS  Google Scholar 

  8. Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol. 2003;56:10–6.

    Article  PubMed  CAS  Google Scholar 

  9. Lazarus HM, Blumer JL, Yanovich S, Schlamm H, Romero A. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol. 2002;42:395–402.

    Article  PubMed  CAS  Google Scholar 

  10. Camuset J, Nunes H, Dombret MC, Bergeron A, Henno P, Philippe B, Dauriat G, Mangiapan G, Rabbat A, Cadranel J. Treatment of chronic pulmonary aspergillosis by voriconazole in non-immunocompromised patients. Chest. 2007;131:1435–41.

    Article  PubMed  Google Scholar 

  11. Kohno S, Izumikawa K, Kakeya H, Miyazaki Y, Ogawa K, Amitani R, Niki Y, Kurashima A. Clinical efficacy and safety of micafungin in Japanese patients with chronic pulmonary aspergillosis: a prospective observational study. Med Mycol. 2011;49:688–93.

    PubMed  CAS  Google Scholar 

  12. Kohno S, Izumikawa K, Ogawa K, Kurashima A, Okimoto N, Amitani R, Kakeya H, Niki Y, Miyazaki Y; Japan Chronic Pulmonary Aspergillosis Study Group (JCPASG). Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J Infect. 2010;61:410–8.

    Article  PubMed  Google Scholar 

  13. Leeflang MM, Debets-Ossenkopp YJ, Visser CE, Scholten RJ, Hooft L, Bijlmer HA, Reitsma JB, Bossuyt PM, Vandenbroucke-Grauls CM (2008) Galactomannan detection for invasive aspergillosis in immunocompromized patients. Cochrane Database Syst Rev (4):CD007394.

  14. Kitasato Y, Tao Y, Hoshino T, Tachibana K, Inoshima N, Yoshida M, Takata S, Okabayashi K, Kawasaki M, Iwanaga T, Aizawa H. Comparison of Aspergillus galactomannan antigen testing with a new cut-off index and Aspergillus precipitating antibody testing for the diagnosis of chronic pulmonary aspergillosis. Respirology. 2009;14:701–8.

    Article  PubMed  Google Scholar 

  15. Loeuille GA, Berthou C, Hilmarsdottir I, et al. Aspergillosis treated with itraconazole: analysis of 64 cases and review of literature. J Mycol Med. 1993;3:1–13.

    Google Scholar 

  16. Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol. 1990;23:607–14.

    Article  PubMed  CAS  Google Scholar 

  17. Gomez-Lopez A, Garcia-Effron G, Mellado E, Monzon A, Rodriguez-Tudela JL, Cuenca-Estrella M. In vitro activities of three licensed antifungal agents against Spanish clinical isolates of Aspergillus spp. Antimicrob Agents Chemother. 2003;47:3085–8.

    Article  PubMed  CAS  Google Scholar 

  18. Jain LR, Denning DW. The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. J Infect. 2006;52:e133–7.

    Article  PubMed  Google Scholar 

  19. Sambatakou H, Dupont B, Lode H, Denning DW. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am J Med. 2006;119:527.e17–24.

    Article  Google Scholar 

Download references

Conflict of interest

The authors state no conflict of interest and have received no payment in preparation of this manuscript.

Author information

Authors and Affiliations

  1. Ibaraki Higashi National Hospital, Ibaraki, Japan

    T. Saito

  2. Dohoku National Hospital, Hokkaido, Japan

    S. Fujiuchi

  3. Fukuoka-Higashi Medical Center, Fukuoka, Japan

    Y. Tao

  4. Chiba-East-Hospital, Chiba, Japan

    Y. Sasaki

  5. Higashi Nagoya National Hospital, Aichi, Japan

    K. Ogawa

  6. Kinki-Chuo Chest Medical Center, Osaka, Japan

    K. Suzuki & M. Sakatani

  7. Minami-Okayama Medical Center, Okayama, Japan

    A. Tada

  8. Okinawa National Hospital, Okinawa, Japan

    M. Kuba

  9. Nagara Medical Center, Gifu, Japan

    T. Kato

  10. Minami Kyusyu National Hospital, Kagoshima, Japan

    M. Kawabata

  11. Tokyo National Hospital, Tokyo, Japan

    A. Kurashima

Authors
  1. T. Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Fujiuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y. Tao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y. Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K. Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Tada
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Kuba
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. T. Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M. Kawabata
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A. Kurashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M. Sakatani
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

NHO Pulmonary Fungosis Research Group

Corresponding author

Correspondence to T. Saito.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saito, T., Fujiuchi, S., Tao, Y. et al. Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan. Infection 40, 661–667 (2012). https://doi.org/10.1007/s15010-012-0322-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15010-012-0322-x

Keywords

Search

Navigation